Breaking the immunosuppressive barrier: an armored CAR-M biotechnology with the original M1 phenotype dominance rescues antitumor immunity - PubMed
7 hours ago
- #immunotherapy
- #CAR-M
- #tumor microenvironment
- CAR-M (Chimeric Antigen Receptor Macrophages) show promise for solid tumor immunotherapy but are limited by M2 polarization in the tumor microenvironment (TME).
- Researchers developed a TME-regulated CAR-M (TMER CAR-M) with M1 phenotype dominance to resist M2 reprogramming and remodel the TME.
- TMER CAR-M enhanced immune cell infiltration (CD4+, CD8+ T cells, NK cells) and reduced immunosuppressive cells (Tregs, myeloid-derived suppressor cells).
- The technology autonomously maintains M1 dominance and reprograms M2 macrophages without antigen stimulation.
- TMER CAR-M offers a clinically translatable platform for immune-cold malignancies, overcoming TME immunosuppression.